Molecular Biomarker Analyses Using Circulating Tumor Cells

por Punnoose, Elizabeth A., Atwal, Siminder K., Spoerke, Jill M., Savage, Heidi, Pandita, Ajay, Yeh, Ru-Fang, Pirzkall, Andrea, Fine, Bernard M., Amler, Lukas C., Chen, Daniel S., Lackner, Mark R.
Publicado 2010

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor

por Ma, Shuguang, Suchomel, Julia, Yanez, Evelyn, Yost, Edward, Liang, Xiaorong, Zhu, Rui, Le, Hoa, Siebers, Nicholas, Joas, Lori, Morley, Roland, Royer‐Joo, Stephanie, Pirzkall, Andrea, Salphati, Laurent, Ware, Joseph A., Morrissey, Kari M.
Publicado 2019

A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastat...

por Lieu, Christopher H., Hidalgo, Manuel, Berlin, Jordan D., Ko, Andrew H., Cervantes, Andres, LoRusso, Patricia, Gerber, David E., Eder, J. Paul, Eckhardt, S. Gail, Kapp, Amy V., Tsuhako, Amy, McCall, Bruce, Pirzkall, Andrea, Uyei, Anne, Tabernero, Josep
Publicado 2017

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

por Shames, David S., Carbon, Juliet, Walter, Kim, Jubb, Adrian M., Kozlowski, Cleopatra, Januario, Tom, An, Do, Fu, Ling, Xiao, Yuanyuan, Raja, Rajiv, Jiang, Brittany, Malekafzali, Ashi, Stern, Howard, Settleman, Jeff, Wilson, Timothy R., Hampton, Garret M., Yauch, Robert L., Pirzkall, Andrea, Amler, Lukas C.
Publicado 2013

Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

por Shames, David S., Carbon, Juliet, Walter, Kim, Jubb, Adrian M., Kozlowski, Cleopatra, Januario, Tom, Do, An, Fu, Ling, Xiao, Yuanyuan, Raja, Rajiv, Jiang, Brittany, Malekafzali, Ashi, Stern, Howard, Settleman, Jeff, Wilson, Timothy R., Hampton, Garret M., Yauch, Robert L., Pirzkall, Andrea, Amler, Lukas C.
Publicado 2013

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

por Spahn, Jessica, Peng, Jing, Lorenzana, Edward, Kan, David, Hunsaker, Thomas, Segal, Ehud, Mautino, Mario, Brincks, Erik, Pirzkall, Andrea, Kelley, Sean, Mahrus, Sami, Liu, Liling, Dale, Stephanie, Quiason, Cristine, Jones, Elizabeth, Liu, Yichin, Latham, Sheerin, Salphati, Laurent, DeMent, Kevin, Merchant, Mark, Hatzivassiliou, Georgia
Publicado 2015

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

por Fayette, Jérôme, Wirth, Lori, Oprean, Cristina, Udrea, Anghel, Jimeno, Antonio, Rischin, Danny, Nutting, Christopher, Harari, Paul M., Csoszi, Tibor, Cernea, Dana, O’Brien, Paul, Hanley, William D., Kapp, Amy V., Anderson, Maria, Penuel, Elicia, McCall, Bruce, Pirzkall, Andrea, Vermorken, Jan B.
Publicado 2016

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

por Nayak-Kapoor, Asha, Hao, Zhonglin, Sadek, Ramses, Dobbins, Robin, Marshall, Lisa, Vahanian, Nicholas N., Jay Ramsey, W., Kennedy, Eugene, Mautino, Mario R., Link, Charles J., Lin, Ray S., Royer-Joo, Stephanie, Liang, Xiaorong, Salphati, Laurent, Morrissey, Kari M., Mahrus, Sami, McCall, Bruce, Pirzkall, Andrea, Munn, David H., Janik, John E., Khleif, Samir N.
Publicado 2018